Kymera Therapeutics shares jumped sharply in morning trading after the company confirmed that enrollment in its BROADEN2 Phase 2b trial of KT-621 has completed nearly six months earlier than previously expected. The stock advanced 21.6% in early trading following the announcement.
The company said the faster-than-anticipated enrollment moves the expected topline data readout to year-end 2026, accelerating the prior guidance of mid-2027 by roughly six months. Kymera also indicated it plans to initiate Phase 3 studies by mid-2027, contingent on regulatory discussions.
Investors have been piling into Kymera in the wake of several recent developments that together strengthened confidence in the company's development pathway. Industry M&A activity helped underscore the commercial appeal of therapies targeting atopic dermatitis and related respiratory conditions; specifically, the AbbVie acquisition of Apogee Therapeutics, valued at about $10.9 billion, was cited by market participants as validating the strategic interest in that therapeutic area. In response to those sector signals, analysts at Truist Securities reiterated a Buy rating on KYMR.
Corporate fundamentals also contributed to the market response. Kymera recently appointed Felix Baker as Board Chairman and reported a cash balance of $1.55 billion as of the first quarter, a position the company says will provide runway into key data-readout periods.
The intraday surge was markedly stronger than broader market movements. The S&P 500 was essentially unchanged while the Nasdaq traded modestly lower as investors digested a hotter-than-expected Personal Consumption Expenditures inflation reading alongside a strong earnings report from Micron Technology. That contrast suggests Kymera's move was driven primarily by company-specific clinical and corporate developments rather than macroeconomic tailwinds.
Market data showed the stock reaching a new 52-week intraday high of $130.05, before trading at $121.41 as of this report. Real-time quote displays during the session showed a level of 120.65, up 20.78 points, or about 20.81%, at 10:36:00 EST on the USD quote.
Taken together, the rapid completion of BROADEN2 enrollment, the sector-level validation from the AbbVie-Apogee deal, and Kymera's cash position and board changes created a confluence of catalysts that pushed the shares markedly higher during the morning session.
What happened - Kymera finished enrollment in BROADEN2 ahead of schedule and moved expected topline results to year-end 2026; plans Phase 3 initiation by mid-2027, subject to regulatory discussions.
Why it matters - Earlier data readout shortens the timeline for potential clinical milestones and was interpreted positively by investors, contributing to a sharp stock move that outpaced the broader market.
Note: All facts in this report are drawn from Kymera Therapeutics' statements and contemporaneous market data released with the company announcement.